| Skip navigation | ||
![]() |
![]() | ![]() |
|
|
||
Immune hemolytic anemia is a condition in which there is a reduced blood cell count due to the premature destruction of red blood cells by the immune system.
Immune hemolytic anemia occurs when antibodies form against the body's own red blood cells. The antibodies will destroy the blood cells because the immune system mistakenly recognizes these blood cells as foreign material within the body. The antibodies may be caused by:
If the cause of antibody formation is disease or medication, it is referred to as secondary immune hemolytic anemia. If the cause is unknown, it is called idiopathic autoimmune hemolytic anemia. This type of anemia accounts for one-half of all immune hemolytic anemias.
Risk factors are related to the causes.
Treatment with a steroid medication such as prednisone is usually the first therapy tried. If a steroid medication does not improve the condition, removal of the spleen (splenectomy) may be considered. Treatments with drugs that suppress the immune system (immunosuppressants) may also be given if you do not respond to steroids.
Blood transfusions, if needed for severe anemia, are given with caution because the blood may not be compatible and it may cause further hemolysis.
The disease may start quickly and be very serious, or it may remain mild and not need specific treatment.
In most people, steroids or splenectomy can control anemia. In others, treatment can usually partially control the anemia.
Severe anemia rarely leads to death. Overwhelming infection may occur as a complication of treatment with steroids, other medications that suppress the immune system, or splenectomy, because these treatments reduce the body's ability to fight infection.
Call your health care provider if you have unexplained fatigue or chest pain, or signs of infection.
Screening for antibodies in donated blood and in the recipient may prevent hemolytic anemia related to blood transfusions.
Anemia - immune hemolytic; Autoimmune hemolytic anemia (AIHA)
Updated by: David C. Dugdale, III, MD, Professor of Medicine, Division of General Medicine, Department of Medicine, University of Washington School of Medicine; and Yi-Bin Chen, MD, Leukemia/Bone Marrow Transplant Program, Massachusetts General Hospital. Also reviewed by David Zieve, MD, MHA, Medical Director, A.D.A.M., Inc.
|
A.D.A.M., Inc. is accredited by URAC, also known as the American Accreditation HealthCare Commission (www.urac.org). URAC's accreditation program is an independent audit to verify that A.D.A.M. follows rigorous standards of quality and accountability. A.D.A.M. is among the first to achieve this important distinction for online health information and services. Learn more about A.D.A.M.'s editorial policy, editorial process and privacy policy. A.D.A.M. is also a founding member of Hi-Ethics and subscribes to the principles of the Health on the Net Foundation (www.hon.ch). |

| Home | Health Topics | Drugs & Supplements | Encyclopedia | Dictionary | News | Directories | Other Resources | |
| Disclaimers | Copyright | Privacy | Accessibility | Quality Guidelines U.S. National Library of Medicine, 8600 Rockville Pike, Bethesda, MD 20894 National Institutes of Health | Department of Health & Human Services |
Page last updated: 29 October 2009 |